Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OOP

Agency reorganizes cancer drug reviews by disease type, while keeping leadership, as expected. After scheduled actions, applications will be migrating to their designated areas within the renamed Office of Hematology and Oncology Products.